View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 6, 2020

Aimmune secures $200m funding from Nestlé Health Science

US-based biopharmaceutical company Aimmune Therapeutics is set to receive $200m in equity investment from Nestlé Health Science.

US-based biopharmaceutical company Aimmune Therapeutics is set to receive $200m in equity investment from Nestlé Health Science.

Free Report
img

How attractive are current investment opportunities in Europe?

Europe has been identified as one of the most favorable regions for investors, seeing high investment activity in the past year. Most of these investments have been through Debt Offering, valued at close to $700 billion. The region has provided attractive investments in a diverse set of companies. Companies who tend to major themes such Digital Media, Cloud, Artificial Intelligence, E-commerce, and Big Data are recording the highest number of deals, with Digital Media recording close to 2,000 deals. However, GlobalData’s whitepaper offers a full view of the market, analyzing less successful or attractive points of investment as well, examining statistics on Equity Offering investments and PE/VC deals. Understand how government agencies for economies around the world use GlobalData Explorer to:  
  • Track the M&A and Capital Raising volumes into their target market
  • Identify the top sectors in the target market attracting the investments
  • For any investment segment, identify the top Investors inside and outside the target economy that are already investing in the Segment
  • Assess and showcase the growth potential for various Industries in the target economy
Don’t miss out on key market insights that can help optimize your next investment – read the report now.
by GlobalData
Enter your details here to receive your free Report.

The latest funding takes Nestlé Health Science’s total investment in Aimmune to $473m.

This increase in Nestlé Health Science’s total ownership in the company to 25.6%, including nearly 20% of voting shares, while the remaining are non-voting preferred shares.

The announcement comes days after Aimmune received the US Food and Drug Administration (FDA) approval for its Palforzia drug to mitigate peanut allergy in children aged four to 17 years.

Palforzia is the first drug approved for this indication. The company will use the latest funds to support the launch of the drug and also develop new medicines for various food allergies.

Aimmune Therapeutics president and CEO Jayson Dallas said: “Nestlé Health Science has been an important equity investor and strategic partner to Aimmune since we entered into our original collaboration in 2016 and we are grateful for their ongoing commitment toward our mutual goal of developing innovative therapies for food allergies.”

In 2016, Nestlé Health Science invested $145m in Aimmune, followed by $30m in February and $98m in November 2018, which increased Nestlé Health Science’s stake to around 19%.

Nestlé Health Science CEO Greg Behar said: “As part of our ongoing commitment to the advancement of science-based nutritional health solutions, our further investment in Aimmune is intended to help assure Palforzia’s longer-term commercial success and allow Aimmune to continue making significant development advances in the field of food allergy treatments.”

In a separate development, Aimmune gained an exclusive licence from Xencor to develop and commercialise investigational antibody XmAb7195, now renamed as AIMab7195, globally.

Xencor originally developed the drug candidate to treat allergic asthma. Initially, Aimmune will explore XmAb7195 as adjunctive therapy for food allergies.

Related Companies

Free Report
img

How attractive are current investment opportunities in Europe?

Europe has been identified as one of the most favorable regions for investors, seeing high investment activity in the past year. Most of these investments have been through Debt Offering, valued at close to $700 billion. The region has provided attractive investments in a diverse set of companies. Companies who tend to major themes such Digital Media, Cloud, Artificial Intelligence, E-commerce, and Big Data are recording the highest number of deals, with Digital Media recording close to 2,000 deals. However, GlobalData’s whitepaper offers a full view of the market, analyzing less successful or attractive points of investment as well, examining statistics on Equity Offering investments and PE/VC deals. Understand how government agencies for economies around the world use GlobalData Explorer to:  
  • Track the M&A and Capital Raising volumes into their target market
  • Identify the top sectors in the target market attracting the investments
  • For any investment segment, identify the top Investors inside and outside the target economy that are already investing in the Segment
  • Assess and showcase the growth potential for various Industries in the target economy
Don’t miss out on key market insights that can help optimize your next investment – read the report now.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology